LIQUIDIA CORPORATION Operating Lease, Liability, Noncurrent
LIQUIDIA CORPORATION (LQDA) had Operating Lease, Liability, Noncurrent of $2.30 million as of 2023-12-31, per its 10-K filed 2024-03-13.
Discontinued › Balance Sheet › Liabilities › Liabilities, Noncurrent
us-gaap:OperatingLeaseLiabilityNoncurrent · last filed 2024-03-13
- 2023-12-31: Operating Lease, Liability, Noncurrent $2.30M.
- 2023-09-30: Operating Lease, Liability, Noncurrent $2.57M.
- 2023-06-30: Operating Lease, Liability, Noncurrent $2.83M.
- 2023-03-31: Operating Lease, Liability, Noncurrent $3.09M.
| Period end | Operating Lease, Liability, Noncurrent | Operating Lease, Liability, Noncurrent as first filed |
|---|---|---|
| 2023-12-31 | $2.30M 10-K · filed 2024-03-13 | |
| 2023-09-30 | $2.57M 10-Q · filed 2023-11-07 | |
| 2023-06-30 | $2.83M 10-Q · filed 2023-08-10 | |
| 2023-03-31 | $3.09M 10-Q · filed 2023-05-08 | |
| 2022-12-31 | $3.33M 10-K · filed 2024-03-13 | |
| 2022-09-30 | $3.57M 10-Q · filed 2022-11-08 | |
| 2022-06-30 | $3.80M 10-Q · filed 2022-08-11 | |
| 2022-03-31 | $4.02M 10-Q · filed 2022-05-12 | |
| 2021-12-31 | $4.23M 10-K · filed 2023-03-20 | $4.23M 10-K · filed 2022-03-17 |
| 2021-09-30 | $4.44M 10-Q · filed 2021-11-03 | |
| 2021-06-30 | $4.63M 10-Q · filed 2021-08-10 | |
| 2021-03-31 | $4.82M 10-Q · filed 2021-05-13 | |
| 2020-12-31 | $5.01M 10-K · filed 2022-03-17 | |
| 2019-12-31 | $5.67M 10-K · filed 2021-03-25 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Amneal Pharmaceuticals, Inc. (AMRX) | $6.326B | 25.62 | |
| RHYTHM PHARMACEUTICALS, INC. (RYTM) | United States | $6.771B | -37.20 |
| Alkermes plc. (ALKS) | $6.844B | 132.74 | |
| Mirum Pharmaceuticals, Inc. (MIRM) | United States | $5.798B | -8.81 |
| Travere Therapeutics, Inc. (TVTX) | United States | $5.712B | -123.10 |
| Oruka Therapeutics, Inc. (ORKA) | United States | $5.663B | -43.76 |
| Cogent Biosciences, Inc. (COGT) | United States | $5.450B | -17.61 |
| IONIS PHARMACEUTICALS INC (IONS) | United States | $7.277B | -23.25 |
| Gossamer Bio, Inc. (GOSS) | United States | $5.355B | -0.65 |
| PTC THERAPEUTICS, INC. (PTCT) | United States | $5.199B | -177.07 |